ASCP Corner: What Constitutes Evidence-Based Pharmacotherapy for Bipolar Disorder? Part 1: First-Line Treatments
J Clin Psychiatry 2007;68(12):1982-1983
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Ever since the term evidence-based medicine (EBM) entered the medical lexicon in 1992,1 there has been much furor among clinicians both in and out of academic circles about what practices do and do not fall within its domain. Randomized controlled trials still provide the greatest level of rigor for determining whether or not an intervention is efficacious. This is largely because the process of randomization, if successful, accounts for confounding biases that might otherwise influence treatment decisions, such as an unwitting tendency to favor (or avoid) certain treatments in patients with particular characteristics.